(Philadelphia,
PA) - Shiriki Kumanyika, PhD, MPH, has been elected
to a one year term as a member of the Board of Trustees
of the International Society on Hypertension in Blacks
(ISHIB), effective July, 2001.
Kumanyika is the associate dean for Health Promotion
and Disease Prevention at the University of Pennsylvania
School of Medicine, where she is also a professor of
epidemiology, a senior scholar in the Center for Clinical
Epidemiology and Biostatistics, and a senior fellow
of Penn's Institute on Aging.
Headquartered in Atlanta, GA, ISHIB is a nonprofit,
professional society of more than 800 members worldwide.
It was founded in 1986 to respond to the disproportionate
rate of high blood pressure and cardiovascular risk
factors present in ethnic populations. Today it has
expanded its scope to include diabetes, stroke, lipid
disorders, and renal disease.
These issues are addressed through accredited professional
medical education programs, research activities, and
patient and community education.
Kumanyika is the author of numerous research articles,
many of which focus on the problems of obesity and overweight
in minority populations. She has served on various national
advisory committees, including the U.S. Dietary Guidelines
Committees, the National Heart, Lung, and Blood Institute
Advisory Council, and the Women's Health Initiative
Advisory committees. Kumanyika is a past Chair of the
Food and Nutrition Section of the American Public Health
Association and the Council on Epidemiology and Prevention
of the American Heart Association. She currently serves
on the Institute of Medicines, Food and Nutrition Board,
as well as the National Board of Directors of the American
Heart Association. Kumanyika is also a member of the
editorial board for Ethnicity & Disease, ISHIB's
international journal, which deals with disease and
health patterns among ethnic minority populations.
As a member of the Board of Trustees, Kumanyika will
assume a leadership position, working to help eliminate
health disparities found in ethnic populations.
# # #
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.